We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Bệnh Bạch Cầu Tế Bào Phôi
MedXY News
EnglishTag

Bệnh Bạch Cầu Tế Bào Phôi

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Regulatory-like FOXP3+Helios+CD4+ T Conventional Cells Correlate with T-Cell Activation After Orca-T Immunotherapy
Hematology-OncologyAllo-HSCTBệnh Bạch Cầu Tế Bào Phôi

Regulatory-like FOXP3+Helios+CD4+ T Conventional Cells Correlate with T-Cell Activation After Orca-T Immunotherapy

By MedXY|May 29, 2026

A study of leukemia patients found that Orca-T transplant therapy increases a regulatory-like CD4+FOXP3+Helios+ T-cell subset early after treatment, and this subset correlates with later T-cell activation, offering a potential biomarker for

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models
Hematology-OncologyAML
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Bệnh Bạch Cầu Tế Bào Phôi

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models

By MedXY|May 27, 2026

MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.

Choosing a Stem Cell Donor: Why Age Matters More in Some Transplants Than Others
AIBệnh Bạch Cầu Tế Bào Phôidonor age

Choosing a Stem Cell Donor: Why Age Matters More in Some Transplants Than Others

By MedXY|May 21, 2026

A major 2026 study suggests donor age affects survival differently in haploidentical and matched unrelated stem cell transplants, offering a more practical framework for choosing the best donor.

Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib
Hematology-OncologyAMLBệnh Bạch Cầu Tế Bào Phôi

Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib

By MedXY|Mar 29, 2026

A study of 48 patients with R/R AML treated with revumenib revealed that 52% experienced dynamic immunophenotypic changes. Achieving MRD-negative morphologic remission significantly improved overall survival, highlighting the necessity for

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities